Kalaris Therapeutics, Inc. (KLRS)

Kalaris Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-71.26	-58.77	-190.42	-168.71	-171.96	-69.78
Depreciation & Amortization	-	0.15	8.29	2.57	1.12	0.07
Stock-Based Compensation	26.96	26.35	40.78	41.32	43.98	9.43
Other Adjustments	-	-10.12	14.87	-1.08	1.2	0.5
Change in Receivables	-	0.21	-0.05	-0.11	-	0.3
Changes in Accounts Payable	-	-28.86	-2.51	-12.62	20.29	2.73
Changes in Accrued Expenses	-	-	-	-	0.4	-0.19
Changes in Income Taxes Payable	-	-	-0.13	-0.88	1.01	-
Changes in Other Operating Activities	-	3.35	4.71	-2.54	-2.34	-3.87
Operating Cash Flow	-79.19	-67.71	-124.45	-142.05	-106.32	-60.81
Capital Expenditures	-	-	-	-	-0.03	-0.24
Purchases of Investments	-	-	-125.83	-228.81	-76.59	-300.26
Proceeds from Sale of Investments	-	95	163.81	148.33	262.6	131
Investing Cash Flow	-	95	37.99	-80.48	185.98	-169.5
Issuance of Common Stock	-	0.02	70.5	126.96	0.23	295.45
Net Common Stock Issued (Repurchased)	-	0.02	70.5	126.96	0.23	295.45
Other Financing Activities	-	-	-	-	-	-3.47
Financing Cash Flow	-	0.02	70.5	126.96	0.23	291.98
Effect of Exchange Rate Changes on Cash and Cash Equivalents	-	-	-	-	-0.04	-0.09
Net Cash Flow	-79.19	27.32	-15.97	-95.57	79.85	61.58
Beginning Cash & Cash Equivalents	-	90.97	106.94	202.51	122.66	61.08
Ending Cash & Cash Equivalents	-79.19	118.29	90.97	106.94	202.51	122.66
Free Cash Flow	-79.19	-67.71	-124.45	-142.05	-106.35	-61.05
Free Cash Flow Per Share	-1.72	-13.52	-27.51	-1.85	-1.69	-2.27
Levered Free Cash Flow	-71.12	-84.14	-180.05	-182.18	-151.52	-71.28
Unlevered Free Cash Flow	-71.12	-90.81	-189.67	-184.94	-148.37	-72.8

Updated Jun 30, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q